Prot #201973: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date3/14/18 → 3/14/21

Funding

  • Parexel (Prot #201973 // Prot #201973)
  • GlaxoSmithKline LLC (Prot #201973 // Prot #201973)